Quoin Pharmaceuticals, Ltd.

Quoin Pharmaceuticals is a clinical-stage pharmaceutical company focused on rare and orphan diseases. Its business model currently centers on research and development, aiming to bring novel therapeutics through clinical trials and regulatory approval. The company does not yet generate revenue, a common characteristic of biotechnology firms in the development phase, and operates in a highly specialized, competitive landscape requiring significant capital investment.

Analysis of the multi-year financials reveals a consistent pattern of net losses, with net income reported at -9.4M in 2022, -8.7M in 2023, -9.0M in 2024, and expanding to -15.8M in 2025. Operating cash flow has also been negative, showing outflows of -8.5M in 2022, -7.9M in both 2023 and 2024, and increasing to -13.5M in 2025. The company maintains a modest cash position, with 3.8M in cash as of 2025, and reports no total debt across the periods provided.

Key strengths for Quoin lie in its focus on niche orphan drug markets, which can offer expedited regulatory pathways and extended market exclusivity if successful. However, significant risks persist, primarily centered on the inherent uncertainties and high costs of clinical development, coupled with the absence of revenue generation. Investors should closely monitor the progress of its drug pipeline through clinical trials, along with its cash burn rate and any future financing activities to support ongoing operations.